Exploring the Economic Evaluation of Pharmacological Treatment of Hypertension Based on Markov Modeling
Department of Medicine, Faculty of Chinese Medicine Science Guangxi University of Chinese Medicine, Nanning 530222, China
| Abstract: | Objective: To conduct long-term economic evaluation of two adjuvant treatments of Gastroma Guteng Yin in the treatment of hypertension and only using conventional western medicine in the treatment of hypertension, so as to provide reasonable basis for intervention drugs for hypertension. Methods: From the perspective of Medicare payers, a Markov model was constructed using the results of the latest clinical studies on the treatment of hypertension with the addition of Tianma Hook Teng Drink combined with antihypertensive drugs as a source of data, through which the development of the disease was simulated, and the cost and utility of the two regimens for the treatment of hypertension were analyzed, after which sensitivity analyses were performed to check the stability of the results. Results: The cumulative cost after 20 years of treatment with Tianma Hook Teng Drink Plus in combination with conventional western medicines was $56,865.29, with a health output of 10.38 QALYs, while the cumulative cost after 20 years of treatment with western medicines only was $5813.91, with a health output of 9.62 QALYs, and an ICER of $51,051.38/QALY. Sensitivity analysis showed that unidirectional and probabilistic sensitivity analysis showed that the results remained unchanged within the acceptable range and did not affect the model results, indicating that the economy was good and could be used. Conclusion: Gastroma Guteng Yin combined with antihypertensive drugs can be used as a better treatment for hypertension, which has good health improvement and economic effects, and can be widely used in clinic. |
| Keywords: | Traditional Chinese Medicine; Gastrodia Guoteng Yin Plus or Minus; Decision Tree; Markov Model; Cost-Effectiveness Analysis |
| DOI: | 10.57237/j.mrf.2024.02.002 |
View:
Downloads:
Received: 27 February 2024
Accepted: 13 May 2024
Published Online: 23 May 2024
Funding
| 1. | 国家自然科学基金项目 (编号: 82204755, 81960751) |
| 2. | 广西中医药大学赛恩斯新医药学院科研项目 (编号: 2022CX004, 2022MS008, 2022QJ001) |
| 3. | 广西中医药大学赛恩斯新医药学院国家级大学生创新训练项目 (202313643007) |
References
| [1] | Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, Wang J, Zhu M, Weintraub WS, Gao R; China Hypertension Survey Investigators. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015. Circulation. 2018; 137(22): 2344-2356. |
| [2] | GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159): 1859-1922. |
| [3] | 马丽媛, 王增武, 樊静, 胡盛寿. 《中国心血管健康与疾病报告2021》关于中国高血压流行和防治现状 [J]. 中国全科医学, 2022, 25(30): 3715-3720. |
| [4] | O'Brien E. The Lancet Commission on hypertension: Addressing the global burden of raised blood pressure on current and future generations. J Clin Hypertens (Greenwich). 2017; 19(6): 564-568. |
| [5] | 杨爽, 白莎, 王恒, 郝春艳.老年高血压患者心功能、外周血管阻力与血清Hcy、血脂水平的相关性研究 [J]. 中国循证心血管医学杂志, 2021, 13(1): 47-50. |
| [6] | 周家谭, 卢健棋, 罗文宽, 杨敏.中药防治高血压靶器官损害相关信号通路的研究进展 [J]. 中国药房, 2023, 34(5): 625-630. |
| [7] | 陈广进, 梁兜选, 李美红. 半夏白术天麻汤加减配合中药沐足治疗顽固性高血压的临床效果 [J]. 中国当代医药, 2021, 28(27): 177-179. |
| [8] | 张美林. 天麻钩藤饮加减煎服联合耳尖放血疗法治疗肝阳上亢型顽固性高血压30例 [J]. 中医外治杂志, 2017, 26(3): 26-27. |
| [9] | 江钰, 王洪霞. 中药穴位贴敷治疗老年高血压病100例临床疗效分析 [J]. 新疆中医药, 2019, 37(5): 20-22. |
| [10] | 李伯阳, 赵英强.中药治疗高血压远期疗效研究进展 [J]. 内蒙古中医药, 2021, 40(12): 148-151. |
| [11] | 张芝芝. 天麻钩藤饮加减辅助治疗肝阳上亢型高血压的临床效果观察 [J]. 世界最新医学信息文摘, 2019, 19(89): 203+206. |
| [12] | 朱亦凡, 黄蓉, 丁怡文, 沃田, 陈磊.氨氯地平和赖诺普利治疗老年高血压的经济学评价——基于Markov模型[J].卫生经济研究, 2019, 36(6): 50-53. |
| [13] | 刘利勤, 李青, 胡明, 李美娟, 杨涵.应用Markov模型对3种血管紧张素Ⅱ受体拮抗剂预防高血压患者卒中和心肌梗死的经济学评价 [J]. 中国药学杂志, 2019, 54(2): 137-143. |
| [14] | 桑海强. 应用Markov模型对高血压病两种初始联合方案治疗效果的药物经济学评价 [D]. 中南大学, 2010(01). |
| [15] | 花思桦, 刘国恩, 孙利华, 连桂玉. 超重与肥胖对高血压患者医疗费用负担的影响 [J]. 卫生经济研究, 2017, (10): 27-29. |
| [16] | 徐婷玲, 周脉耕, 刘江美, 王黎君, 董文兰. 1990年与2019年中国居民归因于高血压的死亡负担分析 [J]. 中国慢性病预防与控制, 2022, 30(5): 327-331+335. |
| [17] | 张文娟, 魏蒙. 中国人口的死亡水平及预期寿命评估——基于第六次人口普查数据的分析 [J]. 人口学刊, 2016, (3): 18-28. |
| [18] | 李海燕, 胡宇千, 于智杰. 缬沙坦/氨氯地平复方制剂与ARB+CCB联用治疗高血压的药物经济学比较 [J]. 中国药房, 2018, 29(17): 2398-2402. |
| [19] | 彭琴. 基于决策树-马尔科夫模型的脑卒中筛查策略的卫生经济学评价 [D]. 天津医科大学, 2020. |
| [20] | 周颖玉, 吴群红. 经济学理论视角下的健康贴现率研究 [J]. 中国卫生经济, 2023, 42(1): 1-3. |
| [21] | 刘月彬, 黄珊, 刘美琴.意愿支付法在中药经济评价中的应用 [J]. 海峡药学, 2013, 25(11): 206-208. |
| [22] | Sun S, Chen J, Johannesson M, et al. Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res. 2011, 20(3): 309-320. |
| [23] | Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation, 1995, 92(10): 2811-2818. |
| [24] | Tengs D, Lin TH. A Meta-Analysis of Quality-of-Life Estimates for Stroke. Pharmacoeconomics, 2003, 21(3): 191-200. |
| [25] | <中国药物经济学评价指南>课题组, 刘国恩, 胡善联, 吴久鸿.中国药物经济学评价指南(2011版) [J]. 中国药物经济学, 2011(3): 6-4811-48. |
| [26] | 马丽媛, 王增武, 樊静等.《中国心血管健康与疾病报告2021》概要 [J]. 中国介入心脏病学杂志, 2022, 30(7): 481-496. |
| [27] | 俞笑平. 高血压药物的合理用药和不良反应 [J]. 中文科技期刊数据库 (全文版) 医药卫生, 2022(1): 29-31. |
| [28] | 中华中医药学会心血管病分会. 高血压中医诊疗专家共识[J]. 中国实验方剂学杂志, 2019, 0(15): 217-221. |
| [29] | 李艳妮, 张鹏, 朱浩. 天麻钩藤饮联合西药治疗原发性高血压的Meta分析 [J]. 巴楚医学, 2022, 5(4): 83-88. |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us